Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

Amgen today is the biggest biotechnology company ... about the ins and outs and trends of HEOR. The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected ...

Amgen’s acquisition will give the company ... (July 8-10, 2025). The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for bio & pharmaceutical ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Amgen on Thursday said its just-launched biosimilar of Johnson & Johnson’s autoimmune drug Stelara ...

Amgen recently reported strong financial results for Q1 2025, showing a turnaround from a loss to a substantial net income. This positive performance included ambitious revenue and earnings ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants. The historically tight-lipped Amgen execs remain judicious ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

In fact, Amgen’s overall revenue of $8.1 billion was a 9% increase year over year and topped the analyst consensus. The lack of success for the Horizon drugs is apparently becoming a sore ...

RBC lowers Amgen price target to $320 but keeps Outperform rating based on steady outlook for MariTide. Goldman sees MariTide efficacy risk in Phase 3 trial due to dose escalation, possibly ...

James Bradner; Executive Vice President, Research and Development, and Chief Scientific Officer; Amgen Inc Peter Griffith; Executive Vice President and Chief Financial Officer; Amgen Inc Good ...